Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.15, delivering a surprise of -25%. Over the last four quarters, the company h ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State or other ...

Exhibit 99.1 Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total DANYELZA net product revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase ● Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong ● Part A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter ...

Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong Part A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024 Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB): TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED THE STOCK OF Y-MABS THERAPEUTICS, INC. ("Y-MABS") BETWEEN OCTOBER 6, 2020 AND OCTOBER 28, 2022, BOTH DATES INCLUSIVE. You are receiving this N ...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. Mr. Pfreundschuh p ...

Mr. Pfreundschuh will be based in Y-mAbs' New York and New Jersey offices. Forward-Looking Statements DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. "I am thrilled to join the Y-mAbs team during this pivotal time for the company," said Mr. Pfreundschuh. "With a solid financial foundation fueled by the growing commercial success of DANYELZA® on a global scale, I believe Y-mAbs is well positioned to further advance our SADA-PRIT technology platform and materially change the way w ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-Investor Relations Michael Rossi - President and Chief Executive Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Bill Maughan - Canaccord Genuity Nick Unan - BMO Capital Markets David Nierengarten - Wedbush Securities Operator Good morning, ...